Research examining effects of shift work found that both excessive sleepiness and insomnia associated with shift work seriously impacted the lives of shift workers.
The research was presented Tuesday, May 17, at the American Psychiatric Association’s 164th Annual Meeting which runs Saturday, May 14, to Wednesday, May 18, 2010 in Honolulu.
The studies found shift workers do not always recognize their own symptoms of shift work disorder; and healthcare professionals believe that shift work disorder is missed two-thirds of the time.
One study used a structured online survey of 260 shift workers and 673 healthcare professionals to examine the impact of excessive sleepiness associated with shift work and diagnosis of shift work disorder.
Shift work negatively impacted respondents’ lives by affecting energy level (72 percent of respondents), emotional health (52 percent), and physical health (51 percent). As a result of their excessive sleepiness, 69 percent had made mistakes at work; 43 percent said their ability to care for dependents had been compromised; and 10 percent had had at least one work-related accident. Half of respondents wanted to change their jobs or work hours and did not feel it was possible to do so.
A second study looked at how shift work disorder was diagnosed from the perspective of healthcare professionals and shift workers. When excessive sleepiness was discussed with health professionals, shift workers initiated the conversation 82 percent of the time, while healthcare professionals initiated it 13 percent. Healthcare professionals believed that 67 percent of shift work disorder is never detected by physicians and that half is undiagnosed because it is often masked by other conditions, including depression.
Both studies were sponsored by and conducted in collaboration with Cephalon, Inc., Frazer, Penn.
The new research posters (#NR10-49 and NR10-39) were scheduled Tuesday, May 17, at the Hawaii Convention Center.
Showing posts with label new research. Show all posts
Showing posts with label new research. Show all posts
Wednesday, May 18, 2011
Tuesday, May 17, 2011
Protein Decline May Link to Depression in Pregnancy
Research from the American Psychiatric Association Annual Meeting shows that a protein important to fetal development declines significantly in the mother’s bloodstream during pregnancy which can cause depression in some pregnant women.
These findings were presented Tuesday, May 17, at the 164th American Psychiatric Association Annual Meeting, being held in Honolulu May 14-18.
Authors concluded that BDNF may be sequestered by the fetus during pregnancy, and that low levels of the protein during pregnancy could put some women at risk for developing depression during pregnancy. The presenters suggested future research on BDNF levels in depressed pregnant women.
These findings were presented Tuesday, May 17, at the 164th American Psychiatric Association Annual Meeting, being held in Honolulu May 14-18.
Researchers looked at levels of brain-derived neurotrophic factor, known as BDNF, a growth-related protein important to healthy fetal development, in the bloodstream of a group of healthy women who were pregnant and compared BDNF levels to women who were not pregnant. Serum BDNF was significantly lower in pregnant women.
Authors concluded that BDNF may be sequestered by the fetus during pregnancy, and that low levels of the protein during pregnancy could put some women at risk for developing depression during pregnancy. The presenters suggested future research on BDNF levels in depressed pregnant women.The American Psychiatric Association is a national medical specialty society whose physician members specialize in the diagnosis, treatment, prevention, and research of mental illnesses, including substance use disorders. Visit the APA at http://www.psych.org/ and http://www.healthyminds.org/.
Study Looks at PTSD Risk Factors
National Guard troops who had some symptoms of posttraumatic stress disorder but not enough to receive a diagnosis before deployment were more vulnerable to PTSD when exposed to combat trauma than other troops, according to a new study released at the American Psychiatric Association Annual Meeting. Researchers found pre-deployment depression and alcohol dependence were not associated with an increased risk for PTSD.
The longitudinal study was scheduled for presentation Tuesday at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18.
Researchers from the University of Medicine and Dentistry, New Jersey, surveyed National Guard Members before and after deployment and compared pre-deployment and post-deployment data for 922 Guard members. The researchers looked at symptoms like intrusive memories, hyperarousal, and avoidance of stimuli associated with a trauma as well as for symptoms of depression and alcohol dependence.
When any of the PTSD symptoms were present prior to deployment, Guard members were at higher risk for a new onset of PTSD after exposure to combat trauma. Guard members screening positive for two out of three components prior to deployment had higher risk than those screen positive for one.
Despite the fact that depression and alcohol dependence frequently found with PTSD, neither was a risk factor in the study.
Study Shows Relationship Between Low Unit Cohesion, Suicidal Thoughts
Unit cohesion appears to be an important factor in determining whether soldiers think about suicide during a period after combat exposure, according to a study presented at the American Psychiatric Association Annual Meeting.
U.S. Army researchers surveyed more than 1,600 soldiers from two combat brigades who had been deployed once. The survey was designed to measure of combat exposure, unit cohesion and self-reported thoughts of suicide. Soldiers who reported higher combat exposure and lower unit cohesion had the greatest odds for reporting suicidal thoughts during the previous four weeks. In addition, soldiers with similar combat exposure were more likely to have suicidal thoughts if they reported less unit cohesion.
The research was scheduled for presentation Tuesday, May 17, at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18.
U.S. Army researchers surveyed more than 1,600 soldiers from two combat brigades who had been deployed once. The survey was designed to measure of combat exposure, unit cohesion and self-reported thoughts of suicide. Soldiers who reported higher combat exposure and lower unit cohesion had the greatest odds for reporting suicidal thoughts during the previous four weeks. In addition, soldiers with similar combat exposure were more likely to have suicidal thoughts if they reported less unit cohesion.
The research was scheduled for presentation Tuesday, May 17, at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18.
Delirium Following Cardiac Surgery Common in Older Patients
Delirium following cardiac surgery, a serious postoperative complication, is fairly common in older patients, affecting more than one-third of those over 70 according to research being presented at the American Psychiatric Association Annual Meeting in Honolulu.
The research poster (NR01-37) is scheduled for presentation on Saturday, May 14, at 10:00 a.m. at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18 at the Hawaii Convention Center.
Delirium is characterized by reduced clarity of awareness of the environment with reduced ability to focus, sustain, or shift attention. The presence of delirium after cardiac surgery has been associated with increase in intensive care stay, in length of hospital stay, sternal wound stability, sternal wound correction, and increased incidence of intubation. Previous research has found rates of delirium following cardiac surgery from two percent to 73 percent.
Researchers led by Adam Lau, M.D. evaluated 50 patients following cardiac surgery and found an overall incidence of delirium of 20 percent with a significant increase in incidence with age. For those over 70 years old, the incidence was 38 percent and for those over age 80, 43 percent. No patients under age 70 developed delirium.
The research poster (NR01-37) is scheduled for presentation on Saturday, May 14, at 10:00 a.m. at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18 at the Hawaii Convention Center.
Delirium is characterized by reduced clarity of awareness of the environment with reduced ability to focus, sustain, or shift attention. The presence of delirium after cardiac surgery has been associated with increase in intensive care stay, in length of hospital stay, sternal wound stability, sternal wound correction, and increased incidence of intubation. Previous research has found rates of delirium following cardiac surgery from two percent to 73 percent.
Researchers led by Adam Lau, M.D. evaluated 50 patients following cardiac surgery and found an overall incidence of delirium of 20 percent with a significant increase in incidence with age. For those over 70 years old, the incidence was 38 percent and for those over age 80, 43 percent. No patients under age 70 developed delirium.
Monday, May 16, 2011
Children of Deployed Parents More Likely to Experience Psychiatric Hospitalization
Children of military service members are more likely to be hospitalized for a psychiatric condition when a parent has been deployed, according to a new study presented at the American Psychiatric Association Annual Meeting.
The research was scheduled for presentation in a press briefing Monday, May 16, at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18
Researchers looked at records for nearly 380,000 children ages 9 to 17 years of active duty military personnel. The children’s data was linked to the parent’s deployment records.
The odds of psychiatric hospitalization increased by 10 percent among children age 9 to 17 years when a military parent was deployed, according to the study. The odds of hospitalization increased with increasing length of a parent’s deployment.Details of this study, along with five other new research studies, will be presented at a press briefing from the APA Annual Meeting. Members of the media can attend in Room 307 of the Hawaii Convention Center at 8 am Hawaii time, Monday, May 16, or participate online at 11 AM PDT/2 pm EDT by registering at https://www2.gotomeeting.com/register/341505819.
The American Psychiatric Association is a national medical specialty society whose physician members specialize in the diagnosis, treatment, prevention, and research of mental illnesses, including substance use disorders. Visit the APA at http://www.psych.org/ and http://www.healthyminds.org/.
Saturday, May 14, 2011
Case Studies: Synthetic Cannabis Linked to Extended Psychosis
Case studies indicate the recreational use of synthetic cannabis may in some cases lead to psychosis that can last for days or months in some cases, according to a study at the American Psychiatric Association Annual Meeting in Hawaii.
Researchers at the Naval Medical Center in San Diego followed ten patients hospitalized for psychosis apparently induced by the use of synthetic cannabis, commonly known as “Spice,” “K2,” “Blaze,” and “Red X Dawn.” These are plant material coated with varying combinations of synthetic cannabinoids, which act on the body in a similar way to chemicals found in cannabis. The compounds have not been approved by the FDA for human consumption and little is known about their safety.
The ten patients studied ranged in age from 21 to 25 years old and after use of “Spice” experienced ongoing psychotic symptoms, including auditory and visual hallucinations, paranoid delusions, odd or flat affect, thought blocking, disorganized speech, thoughts of suicide, insomnia, slowed reaction times, agitation and anxiety. Psychotic symptoms generally resolved between five and eight days after admission, but in some cases continued three months or longer.
The research was scheduled for presentation at 1 p.m. Saturday, May 14, at the American Psychiatric Association 164th Annual Meeting, which runs May 14-18 at the Hawaii Convention Center in Honolulu.
Researchers at the Naval Medical Center in San Diego followed ten patients hospitalized for psychosis apparently induced by the use of synthetic cannabis, commonly known as “Spice,” “K2,” “Blaze,” and “Red X Dawn.” These are plant material coated with varying combinations of synthetic cannabinoids, which act on the body in a similar way to chemicals found in cannabis. The compounds have not been approved by the FDA for human consumption and little is known about their safety.
The ten patients studied ranged in age from 21 to 25 years old and after use of “Spice” experienced ongoing psychotic symptoms, including auditory and visual hallucinations, paranoid delusions, odd or flat affect, thought blocking, disorganized speech, thoughts of suicide, insomnia, slowed reaction times, agitation and anxiety. Psychotic symptoms generally resolved between five and eight days after admission, but in some cases continued three months or longer.
The research was scheduled for presentation at 1 p.m. Saturday, May 14, at the American Psychiatric Association 164th Annual Meeting, which runs May 14-18 at the Hawaii Convention Center in Honolulu.
Electronic Patient Records used to help Identify Biological Causality
Research demonstrating the use of data mining of electronic patient records to study co-morbidity, family predisposition, and finding biological causes for medical conditions otherwise hidden to the eye will be presented at the APA Annual Meeting in Honolulu.
The APA’s 164th Annual Meeting, the world’s largest psychiatric meeting, will run Saturday, May 14 to Wednesday, May 18, 2010 at the Hawaii Convention Center in Honolulu.
The study looked at 10 years of records from Mental Health Centre Sct. Hans, a regional psychiatric hospital in Denmark, on 3,290 patients’ records involving 674 different diagnoses. Of the assigned diagnoses 24% were mental and behavioral disorders. Researchers identified about 270 co-morbidities as unexpected with no know relation. These unexpected co-morbidities were further analyzed to examine whether the co-morbidity could be explained by shared genes, gene-complex, or biological pathways.
For one of these, researchers discovered a previously unrecognized shared biology underlying the two clinical conditions which can be interpreted as a shared genetic predisposition to side effects or to an autoimmune condition.
The new research posters (#NR02-60) were scheduled for presentation Saturday, May 14, at the Hawaii Convention Center.
The APA’s 164th Annual Meeting, the world’s largest psychiatric meeting, will run Saturday, May 14 to Wednesday, May 18, 2010 at the Hawaii Convention Center in Honolulu.
The study looked at 10 years of records from Mental Health Centre Sct. Hans, a regional psychiatric hospital in Denmark, on 3,290 patients’ records involving 674 different diagnoses. Of the assigned diagnoses 24% were mental and behavioral disorders. Researchers identified about 270 co-morbidities as unexpected with no know relation. These unexpected co-morbidities were further analyzed to examine whether the co-morbidity could be explained by shared genes, gene-complex, or biological pathways.
For one of these, researchers discovered a previously unrecognized shared biology underlying the two clinical conditions which can be interpreted as a shared genetic predisposition to side effects or to an autoimmune condition.
The new research posters (#NR02-60) were scheduled for presentation Saturday, May 14, at the Hawaii Convention Center.
Gaming, Internet Have Negative Impact on Teen Sleep
Gaming and Internet activity are more likely to have a negative impact on self-reported teen sleep duration than watching television, according to a study presented at the American Psychiatric Association Annual Meeting.
The research was scheduled for presentation Saturday, May 14, at the 164th American Psychiatric Association Annual Meeting, which is in Honolulu May 14-18.Researchers analyzed data about media usage and physical activity from the 2009 Youth Risk Behavioral Survey maintained by the Centers for Disease Control. The researchers found different types of media exposure have different impact on self-reported teen sleep patterns. Gaming and Internet usage negatively impacted reported sleep time, while television had no impact, and physical activity improved sleep time.
Details of this study, along with five other new research presentations, will be addressed at a press briefing from the APA Annual Meeting. Members of the media can attend in Room 307 of the Hawaii Convention Center at 8 am Hawaii time, Monday, May 16, or participate online at 11 AM PDT/2 pm EDT by registering at https://www2.gotomeeting.com/register/341505819.
The American Psychiatric Association is a national medical specialty society whose physician members specialize in the diagnosis, treatment, prevention, and research of mental illnesses, including substance use disorders. Visit the APA at http://www.psych.org/ and http://www.healthyminds.org/.
Placebo Treatment: Informed Consent not to be Informed
Research examining attitude about use of placebos found people very willing to accept the use of placebos for first line treatment of depression and for other medical conditions. The research will be presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii on May 14.
Researchers led by Uri Nitzan, M.D., used a cross sectional survey to investigate whether subjects suffering from medical conditions in general and depression in particular would consent to receive placebo, and whether receiving placebo would negatively affect their autonomy or doctor patient relationship.
Study participants, 344 college, medical and law school students from Israel, were provided a thorough explanation about the placebo effect and its efficacy and limitations in the treatment of depression and then completed a self report questionnaire.
Seventy percent of study participants expressed consent to receive placebo as a first line treatment if they were they to suffer from depression in the future and 73 percent consented to receive placebo treatment for other medical conditions. Nearly 90 percent did not consider a physician administering a placebo deceitful, nor the act of prescribing it a deceit.
The researchers concluded that “despite the declared disapproval of placebo treatments by the medical establishment, the majority of our study population was willing to use placebo medication in general, and as first line treatment for depression in particular.” The authors invite physicians to rethink and discuss the legitimacy of administering placebos in clinical practice.
The study (NR01 44) will be part of the new research poster session scheduled for May 14, 10 to 11:30 a.m., in room Kamehameha Hall 3, Level 1 (adjacent to the exhibits) in the Hawaii Convention Center at the APA Annual Meeting in Honolulu.
The APA’s 16th Annual Meeting, the world’s largest psychiatric meeting, will run Saturday, May 14 to Wednesday, May 18, 2010 in Honolulu.
Researchers led by Uri Nitzan, M.D., used a cross sectional survey to investigate whether subjects suffering from medical conditions in general and depression in particular would consent to receive placebo, and whether receiving placebo would negatively affect their autonomy or doctor patient relationship.
Study participants, 344 college, medical and law school students from Israel, were provided a thorough explanation about the placebo effect and its efficacy and limitations in the treatment of depression and then completed a self report questionnaire.
Seventy percent of study participants expressed consent to receive placebo as a first line treatment if they were they to suffer from depression in the future and 73 percent consented to receive placebo treatment for other medical conditions. Nearly 90 percent did not consider a physician administering a placebo deceitful, nor the act of prescribing it a deceit.
The researchers concluded that “despite the declared disapproval of placebo treatments by the medical establishment, the majority of our study population was willing to use placebo medication in general, and as first line treatment for depression in particular.” The authors invite physicians to rethink and discuss the legitimacy of administering placebos in clinical practice.
The study (NR01 44) will be part of the new research poster session scheduled for May 14, 10 to 11:30 a.m., in room Kamehameha Hall 3, Level 1 (adjacent to the exhibits) in the Hawaii Convention Center at the APA Annual Meeting in Honolulu.
The APA’s 16th Annual Meeting, the world’s largest psychiatric meeting, will run Saturday, May 14 to Wednesday, May 18, 2010 in Honolulu.
Subscribe to:
Posts (Atom)
